Evidence map›Paper›PMID 29344233›Full record

ArticleOncology letters2017

Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway.

Yi Chen, Wenwei Sun, Ran He, Feiyan Zhang, Hongyu Wang, Panhong Li, Rong-Guang Shao, Xiaoyu Xu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. The Intricate Notch Signaling Dynamics in Therapeutic Realms of Cancer.ACS pharmacology & translational science · 2023
    Review
  3. Review
  4. Anti-endometriosis Mechanism ofFrontiers in pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi ChenCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Wenwei SunCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Ran HeCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Feiyan ZhangCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Hongyu WangCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Panhong LiCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Rong-Guang ShaoLaboratory of Oncology, Ministry of Health Key Laboratory of Antibiotic Bioengineering, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China.
Xiaoyu XuCollege of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P.R. China.
Southwest University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cluster of differentiation (CD)133 is considered a molecular marker of cancer stem cells in hepatocellular carcinoma. In the present study, the effect of lidamycin (LDM) on CD133 expression in hepatocellular carcinoma (Huh7 cells) was evaluated and the potential molecular mechanism was investigated. Flow cytometry analysis, as well as sorting, sphere formation and western-blot assays, were performed

Indexed as

cancer stem cellscluster of differentiation 133hepatocellular carcinomalidamycinNotch signaling pathway

Identifiers

PMID29344233
PMCPMC5755037
OpenAlexW2765368070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.